# RenovoRx, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/RenovoRx, Inc.). ## Overview RenovoRx, Inc. is a U.S.-based life sciences company focused on developing and commercializing targeted drug-delivery solutions for difficult-to-treat cancers. Its core product is RenovoCath, an FDA-cleared local delivery device used to deliver therapeutic agents directly to tumor sites, alongside an ongoing clinical program centered on its TAMP technology platform. ## Products & services • RenovoCath local drug-delivery device • FDA-cleared standalone RenovoCath device sales • TAMP technology platform for targeted delivery • Clinical trial support for oncology applications • Post-marketing registry study participation - **RenovoCath device sales** (100%) — Standalone sales of the RenovoCath delivery device to hospitals and cancer centers. - **Clinical-stage oncology delivery platform** (0%) — Development activities tied to the TAMP platform and related clinical studies. - **Registry and study-use device supply** (0%) — Device supply used in post-marketing registry and investigator-led study settings. - RenovoCath local drug-delivery device - FDA-cleared standalone RenovoCath device sales - TAMP technology platform for targeted delivery - Clinical trial support for oncology applications - Post-marketing registry study participation ## Customers RenovoRx sells primarily to hospitals, cancer treatment centers, and academic oncology institutions that use RenovoCath in interventional oncology procedures. Its early customer base includes high-volume centers, academic medical centers, and National Cancer Institute-designated centers that adopt the device for difficult-to-treat cancers and may reorder as clinical familiarity grows. - **Hospitals and cancer treatment centers** (primary) — Buy RenovoCath for direct use in oncology procedures where targeted local delivery is needed. - **Academic medical centers** (primary) — Adopt the device for specialized interventional oncology cases and early clinical experience. - **National Cancer Institute-designated centers** (primary) — Use RenovoCath in advanced cancer care settings and contribute to broader clinical validation. - **Clinical trial and registry sites** (secondary) — Purchase devices for use in TIGeR-PaC and post-marketing registry studies. - Hospitals and cancer treatment centers buying RenovoCath for procedures - Academic medical centers adopting the device for oncology workflows - National Cancer Institute-designated centers using the platform in trials and care - Repeat customers placing follow-on orders after initial clinical use - Study sites purchasing devices for registry and post-marketing use ## Geography RenovoRx is headquartered in the United States and its commercial activity is centered in the U.S. oncology market. The company also relies on U.S.-based manufacturing through Medical Murray, its primary third-party RenovoCath manufacturer, which ties supply continuity to domestic production capacity. - United States is the core commercial market for RenovoCath - U.S.-based hospitals and cancer centers are the initial customer base - Medical Murray provides primary third-party manufacturing in the U.S. - Commercial expansion depends on adoption across U.S. oncology centers - No country-level revenue disclosure was provided in the excerpts ## Strategy RenovoRx is focused on expanding RenovoCath from an early commercial launch into a broader oncology device franchise by targeting high-volume cancer centers and encouraging repeat orders. It is also using clinical and registry activity to build evidence, expand awareness, and support future adoption, while keeping the commercial model capital-efficient through a small sales footprint and potential partnerships. - **Grow RenovoCath commercial adoption** (short-term) — Recurring device sales are the main path to building a revenue base. - **Expand clinical and real-world evidence** (medium-term) — Clinical familiarity and data can support broader physician adoption. - **Maintain a capital-efficient commercial model** (short-term) — A lean sales structure helps preserve resources while demand develops. - Expand RenovoCath adoption at high-volume cancer centers - Convert early users into repeat customers - Use clinical and registry activity to support commercial credibility - Build a small, capital-efficient sales organization - Evaluate partnerships with larger commercial organizations ## Risks RenovoRx faces the risks typical of an early commercial medtech and life sciences company, including limited operating history, uncertain physician adoption, and dependence on a narrow product set. Its results also depend on successful manufacturing, reimbursement and purchasing dynamics at hospitals, and the ability to convert clinical interest into sustained commercial demand. - **Limited operating history as a revenue-generating company** [high] — The company has only recently begun commercial sales, so future demand and execution are unproven. - **Dependence on a single product platform** [high] — A large share of value creation depends on RenovoCath adoption and expansion into new uses. - **Manufacturing and supply chain dependence** [medium] — RenovoCath is produced by a primary third-party manufacturer, creating supply continuity risk. - **Clinical and regulatory execution risk** [high] — Clinical evidence and FDA-cleared use boundaries influence physician confidence and market expansion. - **Customer adoption and repeat-order risk** [medium] — Sales depend on hospitals and cancer centers integrating the device into procedures and reordering. - Limited commercial history makes demand and execution hard to predict - Revenue depends heavily on adoption of a single device platform - Manufacturing concentration with one primary third-party supplier - Hospital purchasing and clinical adoption cycles can be slow - Clinical trial and registry outcomes can affect market acceptance ## Accounting Revenue is recognized at a point in time when control of RenovoCath transfers to the customer, so shipment and delivery terms can affect quarterly timing. Investors should also watch fair value accounting for the common warrant liability, which can create non-cash volatility in other income or expense, and the treatment of manufacturing costs as either cost of revenue or research and development depending on whether devices are tied to commercial sales or clinical trial use. - **Revenue recognition timing** — Quarterly revenue comparability - **Return reserve estimation** — Net sales and allowances - **Fair value of common warrant liability** — Net loss volatility - **Classification of manufacturing costs** — Gross margin and R&D expense - Point-in-time revenue recognition affects quarter-to-quarter sales timing - Limited return rights require estimates for potential product returns - Fair value changes in warrant liability can swing non-cash earnings - Manufacturing costs shift between R&D and cost of revenue by use case - Clinical trial and registry spending affects expense classification --- *Last updated: 2026-04-29T04:53:22.689803+00:00*